title: Bevacizumab for graft rejection.
authors.forename: Hooman
authors.initials: H
authors.lastname: Harooni
authors.forename: Vandana
authors.initials: V
authors.lastname: Reddy
authors.forename: Timothy
authors.initials: T
authors.lastname: Root
authors.forename: Balamurali
authors.initials: B
authors.lastname: Ambati
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage; D006084:Graft Rejection / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D015948:Keratoplasty, Penetrating; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D014222:Triamcinolone Acetonide / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D011239:Prednisolone; D014222:Triamcinolone Acetonide